LEAN
Vasomotor Symptoms
Wyeth is now a wholly owned subsidiary of PfizerSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Vasomotor Symptoms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Paroxetine Cairo University | Phase 3 | BB |
Oxybutynin Cairo University | Phase 3 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Northwestern University | Phase 2 | CCC |
Fezolinetant Chinese University of Hong Kong | Phase 2 | CCC |
DESVENLAFAXINE Pfizer | Phase 1 | CC |
Same molecule, other indications
LEAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →